Fármacos antitiroideos vinculados al riesgo de malformaciones congénitas | oneGRAVESvoice

bienvenido a oneGRAVESvoice

- una comunidad de enfermedades oculares tiroideas y enfermedad de Graves con carga positiva.
  • ¡Únete hoy!

Fármacos antitiroideos relacionados con el riesgo de malformaciones congénitas


Los bebés nacidos de mujeres que recibieron medicamentos antitiroideos (ATD) para la enfermedad de Graves (EG) durante el primer trimestre del embarazo tienen un mayor riesgo de malformaciones congénitas, encontró un estudio.

“ATD exposure during the first trimester was associated with significantly increased risk for congenital malformations, particularly for pregnancies in which women received prescriptions for MMI [methimazole] or both ATDs” (MMI or propylthiouracil [PTU]), the researchers write.

Gi Hyeon Seo, MD, from Health Insurance Review and Assessment Service, Wonju-si, Gangwon-do, Korea, and colleagues published their findings online today in Annals of Internal Medicine.   

The authors note, however, that the risk to the fetus must be balanced against the mothers’ risks. “Untreated or insufficiently treated GD may result in pregnancy loss and serious fetal and maternal sequelae, providing a compelling indication for timely administration of antithyroid drugs,” the researchers explain.

Fármacos antitiroideos relacionados con el riesgo de malformaciones congénitas